tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Milestone Pharmaceuticals Announces Public Offering for $48.7M

Story Highlights
Milestone Pharmaceuticals Announces Public Offering for $48.7M

Elevate Your Investing Strategy:

Milestone Pharmaceuticals ( (MIST) ) has issued an announcement.

On July 11, 2025, Milestone Pharmaceuticals announced an underwritten public offering of common shares and warrants, expected to raise approximately $48.7 million. The proceeds will support the clinical development and commercial launch of etripamil for PSVT, as well as general corporate purposes, potentially enhancing the company’s market positioning in cardiovascular treatments.

The most recent analyst rating on (MIST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Milestone Pharmaceuticals stock, see the MIST Stock Forecast page.

Spark’s Take on MIST Stock

According to Spark, TipRanks’ AI Analyst, MIST is a Underperform.

Milestone Pharmaceuticals’ overall stock score reflects substantial financial difficulties, including no revenue and negative cash flows. However, the upcoming launch of CARDAMYST provides a potential turnaround opportunity, which is a significant positive factor. Technical indicators suggest a bearish trend, and valuation metrics highlight the lack of earnings and dividends, indicating a speculative investment.

To see Spark’s full report on MIST stock, click here.

More about Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines. The company recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil, intended for the treatment of paroxysmal supraventricular tachycardia (PSVT), an abnormal heart rhythm.

Average Trading Volume: 1,386,876

Technical Sentiment Signal: Sell

Current Market Cap: $83.4M

For an in-depth examination of MIST stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1